单克隆抗体
医学
不利影响
免疫学
疾病
抗体
重症监护医学
药理学
内科学
作者
Akram N. Salah,Amr H. Hashem,Mohamed Bakr Zaki,Ahmed I. Abulsoud,Asmaa M. Atta,Wagiha S. Elkalla,Hebatallah Ahmed Mohamed Moustafa,Walaa A. El‐Dakroury,Fatma Sa’eed El-Tokhy,Jasmine A. ElBoghdady,Nehal I. Rizk,Sherif S. Abdel Mageed,Osama A Mohammed,Mustafa Ahmed Abdel‐Reheim,Hanan M. Alghamdi,Ahmed S. Doghish
摘要
ABSTRACT Monoclonal antibodies (mAbs) are a key class of biotherapeutic medicines used to treat a wide range of diseases, such as cancer, infectious diseases, autoimmune disorders, cardiovascular diseases, and hemophilia. They can be engineered for greater effectiveness and specific applications while maintaining their structural elements for immune targeting. Traditional immunoglobulin treatments have limited therapeutic uses and various adverse effects. That makes mAbs show rapid growth in the pharmaceutical market, with over 250 mAbs in clinical studies. Although mAbs offer higher specificity, they are less effective against complex antigens. They have become essential in treating diseases with limited medical options, providing innovative solutions that improve patients' quality of life through increasing survival rates, shortening the length of stay in hospitals with an improved treatment outcome, and reducing side effects. This review outlines the mechanisms, applications, and advancements of mAbs, highlighting their transformative role in modern medicine and their potential to shape future therapeutic interventions.
科研通智能强力驱动
Strongly Powered by AbleSci AI